Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Antimicrob Agents ; 31(1): 37-45, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18006283

RESUMO

Tuberculosis (TB) is a leading cause of death amongst infectious diseases. The low permeation of antimycobacterial agents and their difficult access to infected macrophages necessitate long-term use of high drug doses. Liposomes preferentially accumulate in macrophages, increasing the efficacy of antibiotics against intracellular parasites. In the present work, several rifabutin (RFB) liposomal formulations were developed and characterised and their in vivo profile was compared with free RFB following intravenous administration. With the RFB liposomal formulations tested, higher concentrations of the antibiotic were achieved in liver, spleen and lungs 24h post administration compared with free RFB. The concentration of RFB in these organs was dependent on the rigidity of liposomal lipids. The liposomal RFB formulation prepared with dipalmitoyl phosphatidylcholine:dipalmitoyl phosphatidylglycerol (DPPC:DPPG) was the most effective and was selected for biological evaluation in a mouse model of disseminated TB. Compared with mice treated with free RFB, mice treated with the DPPC:DPPG RFB formulation exhibited lower bacterial loads in the spleen (5.53 log(10) vs. 5.18 log(10)) and liver (5.79 log(10) vs. 5.41 log(10)). In the lung, the level of pathology was lower in mice treated with encapsulated RFB. These results suggest that liposomal RFB is a promising approach for the treatment of extrapulmonary TB in human immunodeficiency virus co-infected patients.


Assuntos
Antituberculosos/administração & dosagem , Rifabutina/administração & dosagem , Tuberculose/tratamento farmacológico , Animais , Antituberculosos/farmacocinética , Antituberculosos/uso terapêutico , Química Farmacêutica , Lipossomos , Fígado/química , Fígado/microbiologia , Pulmão/química , Pulmão/microbiologia , Pulmão/patologia , Camundongos , Camundongos Endogâmicos BALB C , Rifabutina/farmacocinética , Rifabutina/uso terapêutico , Baço/química , Baço/microbiologia , Fatores de Tempo
2.
Eur J Pharm Sci ; 11(4): 285-90, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11033071

RESUMO

This paper describes the synthesis and the antiplatelet properties of new heterotricyclic N-acylhydrazone derivatives (7a-e), structurally analogous to known hetrazepinic PAF antagonists, exploring molecular hybridization as a tool for molecular designing. The synthetic route employed to access compounds (7a-e) used, as starting material, the previously described methyl 3-hydroxy-8-methyl-6-phenyl-6H-pyrazolo[3,4-b]thieno[2, 3-d]pyridine-2-carboxylate derivative. The results from inhibitory effects of these novel acylhydrazone derivatives (7a-e) upon PAF-induced platelet aggregation, indicated that all compounds present a significant antithrombotic profile.


Assuntos
Modelos Moleculares , Fator de Ativação de Plaquetas/antagonistas & inibidores , Inibidores da Agregação Plaquetária/química , Inibidores da Agregação Plaquetária/farmacologia , Animais , Azepinas/química , Azepinas/farmacologia , Coelhos , Triazóis/química , Triazóis/farmacologia
3.
Curr Top Med Chem ; 8(7): 579-91, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18473884

RESUMO

The clinical management of tuberculosis and other mycobacterial diseases with antimycobacterial chemotherapy remains a difficult task. The classical treatment protocols are long-lasting; the drugs reach mycobacteria-infected macrophages in low amounts and/or do not persist long enough to develop the desired antimycobacterial effect; and the available agents induce severe toxic effects. Nanotechnology has provided a huge improvement to pharmacology through the designing of drug delivery systems able to target phagocytic cells infected by intracellular pathogens, such as mycobacteria. Liposomes and nanoparticles of polymeric nature represent two of the most efficient drug carrier systems that after in vivo administration are endocytosed by phagocytic cells and then release the carried agents into these cells. This article reviews the relevant publications describing the effectiveness of the association of antimycobacterial agents with liposomes or nanoparticles for the treatment of mycobacterioses, particularly for Mycobacterium tuberculosis and M. avium infections. The increased therapeutic index of antimycobacterial drugs; the reduction of dosing frequency; and the improvement of solubility of hydrophobic agents, allowing the administration of higher doses, have been demonstrated in experimental infections. These advantages may lead to new therapeutic protocols that will improve patient compliance and, consequently, lead to a more successful control of mycobacterial infections. The potential therapeutic advantages resulting from the use of non-invasive administration routes for nanoparticulate systems are also discussed.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Sistemas de Liberação de Medicamentos , Infecções por Mycobacterium/tratamento farmacológico , Antibacterianos/química , Humanos , Lipossomos , Infecções por Mycobacterium/epidemiologia , Infecções por Mycobacterium/etiologia , Nanopartículas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA